This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Textiles del Hogar S.L. (B)
Ormazabal, Gaizka; Vázquez- Dodero, Juan CarlosCase ASN-42-EBusiness Ethics and Corporate Social ResponsibilityThings have changed a little in the 12 months since the estate agent's offer when the business seemed about to close down: results have continued to be good but the future of the business remains highly uncertain and the property business is in a slump ¿.Starting at €5.74
-
Textiles del Hogar S.L. (B)
Ormazabal, Gaizka; Vázquez- Dodero, Juan CarlosCase ASN-42Business Ethics and Corporate Social ResponsibilityDoce meses después de la oferta inmobiliaria para el cierre de la empresa, las circunstancias han cambiado un poco: los resultados siguen siendo muy buenos, pero el futuro del negocio continúa siendo altamente incierto y el mercado inmobiliario ha sufrido un parón...Starting at €5.74
-
Textiles del Hogar S.L.
Vázquez- Dodero, Juan Carlos; Ormazabal, GaizkaCase ASN-40Business Ethics and Corporate Social ResponsibilityTextiles del Hogar, S.L. es una empresa catalana con más de medio siglo de historia que pasó de ser un negocio muy rentable a despertar serias dudas sobre su viabilidad, como consecuencia del declive del sector textil en el ámbito europeo. A ello se suma que, hasta la entrada de los Quesada, la empresa había sido gestionada de forma deficiente. Al hacerse cargo de la compañía, Ramón y Jorge Quesada intentan, sin éxito, encontrar una solución defi...Starting at €8.20
-
Textiles del Hogar S.L.
Vázquez- Dodero, Juan Carlos; Ormazabal, GaizkaCase ASN-40-EBusiness Ethics and Corporate Social ResponsibilityTextiles del Hogar, S.L. is a Catalan company with more than half a century of history, which, from being a very profitable business, began to arouse serious doubts about its viability, as a consequence of the decline in the European textile sector. As well as this, until the arrival of the Quesadas, the company had been poorly managed. On taking over, Ramón and Jorge Quesada tried, without success, to find a definitive solution for the business....Starting at €8.20
-
Comergent Technologies Inc.: Enterprise E-Commerce, Teaching Note
Rangan, V. Kasturi; Bellfor, MarieTeaching Note HBS-507087-EMarketingTeaching Note to (505-016). An abstract is not available for this product.Starting at €0.00
-
Akshaya Patra: Impact at Scale
Rangan, V. Kasturi; Appleby, SarahCase HBS-517028-EAkshaya Patra, an Indian NGO, had set an ambitious goal of serving 5 million free meals daily to India's schoolchildren. Founded in 2000, Akshaya Patra had thus far opened 25 high-capacity kitchens in 10 different States to provide a midday meal to nearly 1.65 million school children every day. With 110 million children in 1 million schools eligible for a mandatory midday meal, there was room to grow. Shridhar Venkat, its CEO, had to devise a pla...Starting at €8.20
-
Peabody Essex Museum: What Next
Rangan, V. Kasturi; Rayport, JeffreyCase HBS-520009-EMarketingDan Monroe, successful CEO of PEM, engineered a major transformation. Successor will either stay or change the course. The case describes the 25-year transformation of Peabody Essex Museum, which was created in 1993 by the merger of two sub-scale predecStarting at €8.20
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Case HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
Los Nuevos Horizontes de Dell
Rangan, V. Kasturi; Bell, MarieCase HBS-503S30MarketingFundada en 1984, Dell Corp. ha logrado un crecimiento fenomenal, y para 2000 había superado los $ 25 mil millones en ventas y más de $ 2 mil millones en ingresos netos. En el cuarto trimestre de 2000, sin embargo, la tasa de crecimiento promedio de 30 años de la industria del PC se estrelló a un negativo del 10%. Dell debe tomar decisiones difíciles sobre cómo mantener su rentabilidad a la luz de su amplia cartera de productos - PC, estaciones de...Starting at €8.20